Compare ASPS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | ACET |
|---|---|---|
| Founded | 1999 | 1947 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 71.3M |
| IPO Year | N/A | N/A |
| Metric | ASPS | ACET |
|---|---|---|
| Price | $6.09 | $8.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 26.4K | ★ 208.6K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | N/A |
| Revenue This Year | $38.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $899.06 | ★ N/A |
| Revenue Growth | ★ 10.68 | N/A |
| 52 Week Low | $4.92 | $7.15 |
| 52 Week High | $15.96 | $17.44 |
| Indicator | ASPS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 71.69 |
| Support Level | $5.55 | $7.76 |
| Resistance Level | $6.06 | $9.00 |
| Average True Range (ATR) | 0.42 | 0.48 |
| MACD | 0.06 | -0.18 |
| Stochastic Oscillator | 39.66 | 44.62 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.